This study will evaluates the safety and efficacy of Chimeric antigen receptor T cells (CAR-T) in treating central nervous system B-cell acute lymphocytic leukemia.
CNS leukemia is defined as unequivocal evidence of leukemic blasts in the cerebrospinal fluid by cytology or flow cytometry; cranial palsies or a nonhemorrhagic mass seen in cranial computed tomography or magnetic resonance imaging because of infiltration by leukemia cells
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
CNS leukemia is defined as unequivocal evidence of leukemic blasts in the cerebrospinal fluid by cytology or flow cytometry; cranial palsies or a nonhemorrhagic mass seen in cranial computed tomography or magnetic resonance imaging because of infiltration by leukemia cells
The First Affiliated Hospital of Soochow University
Suzhou, China
RECRUITINGThe complete remission (CR) rate
The safety of the humanized CD19 CAR-T cells treatment will be evalated and the maximum tolerated dose will be determined
Time frame: Participants will be followed for the duration of the treatment, an expected average of 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.